BioLineRx Goodwill and Intangible Assets 2012-2024 | BLRX

BioLineRx goodwill and intangible assets from 2012 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

BioLineRx Goodwill and Intangible Assets 2012-2024 | BLRX

BioLineRx goodwill and intangible assets from 2012 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$78.6B
Takeda Pharmaceutical (TAK)$44.1B
Merck (MKKGY)$21.2B
Astellas Pharma (ALPMY)$20.4B
Sandoz Group AG (SDZNY)$19.7B
United Therapeutics (UTHR)$18B
Summit Therapeutics (SMMT)$15.6B
Neurocrine Biosciences (NBIX)$12.6B
Shionogi (SGIOY)$12.5B
Catalent (CTLT)$10.9B
Madrigal Pharmaceuticals (MDGL)$7.7B
Jazz Pharmaceuticals (JAZZ)$7.4B
Orion OYJ (ORINY)$6.8B
Ionis Pharmaceuticals (IONS)$6.1B
Corcept Therapeutics (CORT)$5.7B
Crinetics Pharmaceuticals (CRNX)$4.8B
PTC Therapeutics (PTCT)$3.3B
Dyne Therapeutics (DYN)$2.9B
Catalyst Pharmaceuticals (CPRX)$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.7B
Soleno Therapeutics (SLNO)$2.5B
NewAmsterdam Pharma (NAMS)$2B
Recursion Pharmaceuticals (RXRX)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
Harrow (HROW)$1.8B
Ocular Therapeutix (OCUL)$1.7B
Xencor (XNCR)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
ARS Pharmaceuticals (SPRY)$1.6B